BAYER PHARMA AG
Manufacturer adverse-event records for BAYER PHARMA AG come from the U.S. Food & Drug Administration (FDA) MAUDE database via openFDA, refreshed March 2026 - see our methodology. Not medical advice.
FDA MAUDE device safety record · 2009–2026 · heavy-book · typical Death-code · injury-heavy
Injury-mix signature
BAYER PHARMA AG leans injury-heavy in event_type mix
Injury-coded event_type share is 98.3% (injury-heavy tercile) beside 0.16% Death-coded (typical). Volume band: heavy.
What the Injury-mix reading shows for BAYER PHARMA AG
The standout signal for BAYER PHARMA AG is Injury-mix: 98.3% Injury-coded (injury-heavy) beside 0.16% Death-coded, on a heavy-book footprint.
As a heavy-book manufacturer, portfolio size and reporting obligations inflate absolute counts - pair BAYER PHARMA AG with device-family pages before treating company totals as a safety verdict. Event_type Death and Injury are one code per report; Patient Outcomes below use a separate FDA population.
Reports span 2 device types, led in this extract by Injury at 62,270 (98.3% of event_type total). Peak single-year volume reaches 16,047 reports across 18 years. These are raw FDA submissions, not adjudicated findings. Snapshot . Verify current communications on the FDA MDR page.
Event Types
Patient Outcomes
FDA patient-outcome codes (separate from event_type). Percentages use this chart's row total.
Devices (2)
| Device | Reports |
|---|---|
| Transcervical Contraceptive Tubal Occlusion Device | 63,338 |
| Laparoscopic Contraceptive Tubal Occlusion Device | 1 |
Yearly Trend
Read our methodology - how this data is sourced, computed, and verified.